Home > Products > CD19 & CD89 > Recombinant Anti-CD19 x Anti-CD89 Bispecific Antibody (Tandem Diabody)

Recombinant Anti-CD19 x Anti-CD89 Bispecific Antibody (Tandem Diabody)  (CAT#: T-BSDB-045)

Recombinant Anti-CD19 x Anti-CD89 Bispecific Antibody (Tandem Diabody) is designed to be expressed as a monomeric subunit (single chain Diabody, scDb), with four variable domains from two parental antibodies. Then the two peptide chains can dimerize in a head-to-tail fashion. This BsAb can retarget macrophages to tumor cells. It is designed for the research of B cell lymphoma; Leukemia therapy.
Datasheet INQUIRY

Specifications

Targets
CD19 & CD89
Species Reactivity
Human
Application
FuncS; Promising therapeutic agent
Related Disease
B cell lymphoma; Leukemia

Targets

Target 1
CD19
Gene ID
UniProt ID
Alternative Names
CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
Target 2
CD89
Gene ID
UniProt ID
Alternative Names
FcαRI; FCAR; Fc fragment of IgA, receptor for; CD89; FcalphaRI; immunoglobulin alpha Fc receptor; Fc alpha receptor
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Online Inquiry

Related products of "CD19 & CD89"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD19 x Anti-CD89 Bispecific Antibody (Tandem Diabody) (T-BSDB-045). Click the button below to contact us or submit your feedback about this product.